Alfasin XR tablet: Each extended release tablet contains Alfuzosin Hydrochloride BP 10 mg.
Alfuzosin Hydrochloride is a selective antagonist of post-synaptic a1 adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Alfuzosin Hydrochloride relaxes the tone of the prostate smooth muscle, prostate capsule, bladder neck and proximal urethra. It competitively and selectively binds to the post synaptic a1-adrenergic receptors in the lower urinary tract. It also relaxes sympathetic nervous stimulation, reduces resting urethral pressure and inhibits urethral hypertonia-induced sympathetic nervous stimulation. As an uroselective agent, Alfuzosin Hydrochloride preferentially binds to prostatic a1 receptors, blockage of these receptors result in reduction of BPH symptoms, improvement of urine flow and decreased potential for hypertensive events.
Alfuzosin Hydrochloride is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia(BPH), lower urinary tract symptoms (LUTS) including urinary frequency, nocturia, incomplete emptying and urinary hesitancy associated with BPH.
The recommended dosage is one 10 mg Alfuzosin Hydrochloride tablet daily to be taken immediately after the same meal each day. The tablets should not be chewed or crushed.
This formulation is generally well tolerated. However the following adverse events have been reported include abdominal pain, dyspepsia, constipation, nausea, impotence, bronchitis, sinusitis and pharyngitis.
Alfuzosin Hydrochloride should not be given to patients with moderate or severe hepatic insufficiency. Caution should be exercised when Alfuzosin is administered in patients with severe renal insufficiency. If symptoms of angina pectoris should newly appear or worsen, Alfuzosin Hydrochloride should be discontinued.
Alfuzosin Hydrochloride is not indicated for use in pregnant and lactating mother.